184 related articles for article (PubMed ID: 32649488)
21. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
22. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB
Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.
Saif MW; Choma A; Salamone SJ; Chu E
J Natl Cancer Inst; 2009 Nov; 101(22):1543-52. PubMed ID: 19841331
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Lazar A; Jetter A
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209
[TBL] [Abstract][Full Text] [Related]
25. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
26. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
27. How can we best monitor 5-FU administration to maximize benefit to risk ratio?
Goirand F; Lemaitre F; Launay M; Tron C; Chatelut E; Boyer JC; Bardou M; Schmitt A
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1303-1313. PubMed ID: 30451549
[TBL] [Abstract][Full Text] [Related]
28. Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.
Di Paolo A; Danesi R; Ciofi L; Vannozzi F; Bocci G; Lastella M; Amatori F; Martelloni BM; Ibrahim T; Amadori D; Falcone A; Del Tacca M
Ther Drug Monit; 2005 Jun; 27(3):362-8. PubMed ID: 15905808
[TBL] [Abstract][Full Text] [Related]
29. [Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography].
Nakamura A; Kikuchi K; Ohishi T; Masuike T
Gan To Kagaku Ryoho; 2004 Mar; 31(3):381-6. PubMed ID: 15045945
[TBL] [Abstract][Full Text] [Related]
30. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
[TBL] [Abstract][Full Text] [Related]
31. How may anticancer chemotherapy with fluorouracil be individualised?
Ploylearmsaeng SA; Fuhr U; Jetter A
Clin Pharmacokinet; 2006; 45(6):567-92. PubMed ID: 16719540
[TBL] [Abstract][Full Text] [Related]
32. Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.
Launay M; Dahan L; Duval M; Rodallec A; Milano G; Duluc M; Lacarelle B; Ciccolini J; Seitz JF
Br J Clin Pharmacol; 2016 Jan; 81(1):124-30. PubMed ID: 26392323
[TBL] [Abstract][Full Text] [Related]
33. Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: A surrogate biomarker for dihydropyrimidine dehydrogenase activity.
Kobuchi S; Akutagawa M; Ito Y; Sakaeda T
Biopharm Drug Dispos; 2019 Jan; 40(1):44-48. PubMed ID: 30592773
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.
van Kuilenburg AB; Maring JG
Pharmacogenomics; 2013 May; 14(7):799-811. PubMed ID: 23651027
[TBL] [Abstract][Full Text] [Related]
35. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
36. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
[TBL] [Abstract][Full Text] [Related]
37. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic drug monitoring of 5-fluorouracil.
Lee JJ; Beumer JH; Chu E
Cancer Chemother Pharmacol; 2016 Sep; 78(3):447-64. PubMed ID: 27217046
[TBL] [Abstract][Full Text] [Related]
39. Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil.
Kobuchi S; Hayashi A; Taniguchi M; Ito Y; Tamura T; Sakaeda T
Cancer Chemother Pharmacol; 2016 Sep; 78(3):517-23. PubMed ID: 27417318
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
